)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Organon
Organon (OGN) investor relations material
Organon Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
Q3 2026 revenue was $1.574B, down 2% YoY; net income rose to $164M from $160M, while diluted EPS was $0.60 versus $0.61.
Nine-month revenue declined 2% to $4.592B, while net income increased to $418M from $392M; Jada’s divestiture and favorable FX supported reported results.
Financial highlights
Q3 gross profit increased 1% to $869M; cost of sales fell 5% to $705M. Nine-month gross profit fell 3% to $2.499B.
Q3 SG&A rose 1% to $421M and R&D declined 1% to $83M; nine-month SG&A fell 1% to $1.279B and R&D fell 3% to $266M.
Nine-month operating cash flow was $702M versus $559M; investing cash flow was $266M provided, versus $325M used in 2025.
Favorable FX added ~$12M, or 1%, to Q3 sales and ~$130M, or 3%, to nine-month sales; excluding FX, sales declined 3% and 5%, respectively.
Outlook and guidance
The Sun Pharma transaction is expected to close by early 2027, subject to remaining customary closing conditions and regulatory approvals; stockholders approved it in July 2026.
Miudella U.S. commercial sales are estimated to launch in late 2026; Epyztek in Australia is expected to launch in H1 2027.
Nexplanon’s EU five-year-use application remains under review, with potential approval in 2027; Vtama international launches are planned for 2026 and beyond, subject to health authority review and approval.
China VBP is expected to pressure general medicines for several more quarters; supply-chain recovery remains ongoing, with mitigation actions underway.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Organon
- Revenue and net income fell as biosimilar growth offset declines in core brands; Sun Pharma deal advances.OGN
Q2 2026 - Merger with Sun Pharma USA and related executive compensation were approved by shareholders.OGNEGM 2026
- Stockholders to vote on Sun Pharma merger amid litigation and new proxy disclosures.OGNProxy filing
- All management proposals passed, with strong financial growth and a focus on women's health and deleveraging.OGNAGM 2025
- Shareholders to vote on $14.00 per share all-cash merger with Sun Pharma USA, board recommends approval.OGNProxy filing
- Shareholders will soon vote on the Sun Pharma acquisition amid strong performance and cultural focus.OGNProxy filing
- All proposals passed, with director elections and executive compensation approved by shareholders.OGNAGM 2026
- Shareholders to vote on $14.00 per share all-cash merger with Sun Pharma USA, closing expected in 2027.OGNProxy filing
- Net income rose 68% to $146 million on $1.46 billion revenue, with a pending merger and remediation.OGNQ1 2026
Next Organon earnings date
Q4 202611 Feb, 2027
Organon
Next Organon earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. The company operates under the Organon & Co. Pharmaceuticals and Organon brands. Its products include hormone contraceptives; biosimilars; women's health products consisting of fertility, menopause, contraception, osteoporosis and gynecological cancer; and treatments for psychiatric and neurological disorders comprising schizophrenia, bipolar mania disorder and depression. The company also offers food animal health products, including pain relief for horses, cattle and sheep; and anti-infectives for poultry.